Theralase CEO describes our licensed photosensitizers for cancer therapy on CBC TV!

President and CEO of Theralase, Roger Dumoulin-White, discusses the Company's progress on  its ground breaking anti-cancer research on CBC’s The Lang and O’Leary Exchange

Read more …

Our invited submission to J. Phys. Chem. A has been accepted!

This article highlights the versatility of 3IL excited states in achieving potent PDT in cancer cells, but also against bacteria. Notably, this PDI effect extends to bacteria growing as a resilient biofilm.

Read more …

Milestone reached in pre-clinical development!

Our licensed compound TLD-1433 has been identified as the lead photodynamic compound for human clinical trials!

Read more …

Poster win at CSC 2014!

Jordan Gibson and Mat Stephenson present posters of their Honours work at the 97th Canadian Chemistry Conference and Exhibition in Vancouver, BC!

Read more …

Our photosensitizers for Theralase anti-cancer photodynamic therapy nears human trials!

The latest research on Photo Dynamic Compound (PDC) technology from Theralase Technologies, proven effective in the destruction of bacteria and cancer, was peer reviewed and invited to be published in Coordination Chemistry Reviews as the company prepares for human clinical trials.

Read more …